Outcomes of Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older
Rachel Gorham(Vanderbilt University Medical Center), Salyka Sengsayadeth(VA Tennessee Valley Healthcare System), Reena Jayani(Vanderbilt University Medical Center), James H. Jerkins(Vanderbilt University Medical Center), Olalekan O. Oluwole(Vanderbilt University), Christina Snider(Vanderbilt University Medical Center), Adetola A. Kassim(Vanderbilt University), Andrew Jallouk(Vanderbilt University Medical Center), Tae Kon Kim(Vanderbilt University), Wichai Chinratanalab(VA Tennessee Valley Healthcare System), Chiu-Lan Chen(Vanderbilt University Medical Center), Bipin N. Savani(Vanderbilt University Medical Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Eden Biltibo(Vanderbilt University Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782